Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for GeneDx Holdings (WGS) over the last 5 years, with Dec 2024 value amounting to $27.5 million.

  • GeneDx Holdings' Shares Outstanding (Weighted Average) rose 6.65% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of $27.5 million for FY2024, which is 6.13% up from last year.
  • Per GeneDx Holdings' latest filing, its Shares Outstanding (Weighted Average) stood at $27.5 million for FY2024, which was up 6.13% from $25.9 million recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' Shares Outstanding (Weighted Average) ranged from a high of $27.5 million in FY2024 and a low of $7.2 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $21.7 million, with a median of $25.9 million in 2023.
  • Data for GeneDx Holdings' Shares Outstanding (Weighted Average) shows a peak YoY soared of 120.84% (in 2023) over the last 5 years.
  • GeneDx Holdings' Shares Outstanding (Weighted Average) (Yearly) stood at $7.2 million in 2020, then increased by 1.26% to $7.3 million in 2021, then soared by 60.32% to $11.7 million in 2022, then surged by 120.84% to $25.9 million in 2023, then rose by 6.13% to $27.5 million in 2024.